New hope for Tough-to-Treat lymphoma: experimental drug combo enters phase 3 trial
NCT ID NCT07562022
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a new drug called SCTB35, combined with lenalidomide, works better than the standard rituximab-plus-lenalidomide combo for people with follicular lymphoma that has returned or not responded to treatment. About 93 adults aged 18-80 will take part. The study will measure side effects, how long the cancer stays under control, and overall response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCTB35 (an experimental drug) combined with lenalidomide
What this could lead to
If successful, this could offer a new treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
What could go wrong
This is an early-stage Phase 3 trial with only 93 participants, so results may not apply to all patients. The experimental drug SCTB35 may cause side effects or not work better than the standard combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China